Constrictive Pericarditis and Pleuropulmonary Disease Linked to Ergot Dopamine Agonist Therapy (Cabergoline) for Parkinson's Disease
- 1 April 1999
- journal article
- case report
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 74 (4) , 371-375
- https://doi.org/10.4065/74.4.371
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Cabergoline in Parkinson's disease complicated by motor fluctuationsMovement Disorders, 1996
- Adjunctive Cabergoline Therapy of Parkinson's Disease: Comparison with Placebo and Assessment of Dose Responses and Duration of EffectClinical Neuropharmacology, 1996
- Fluctuating Parkinson's DiseaseArchives of Neurology, 1994
- Multicenter study of cabergoline, a long‐acting dopamine receptor agonist, in Parkinson's disease patients with fluctuating responses to levodopa/carbidopaNeurology, 1993
- Controlled study of the antiparkinsonian activity and tolerability of cabergolineNeurology, 1993
- Pleuropulmonary disease associated with dopamine agonist therapyAnnals of Neurology, 1991
- Effectiveness and Tolerability of Long Term Treatment with Cabergoline, a New Long-Lasting Ergoline Derivative, in Hyperprolactinemic Patients*Journal of Clinical Endocrinology & Metabolism, 1989
- Pleuropulmonary Disease During Bromocriptine Treatment of Parkinson's DiseaseArchives of internal medicine (1960), 1988
- Simulation of acute myopericarditis by constrictive pericardial disease with endomyocardial fibrosis due to methysergide therapyJournal of the American College of Cardiology, 1984
- PLEUROPULMONARY CHANGES DURING LONG-TERM BROMOCRIPTINE TREATMENT FOR PARKINSON'S DISEASEThe Lancet, 1981